Get the Stockscreener App
1.56
0.64%
-0.01
Gain Therapeutics Inc stock is traded at $1.56, with a volume of 148.26K.
It is down -0.64% in the last 24 hours and down -6.02% over the past month.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
See More
Previous Close:
$1.57
Open:
$1.55
24h Volume:
148.26K
Relative Volume:
0.48
Market Cap:
$41.38M
Revenue:
$210.70K
Net Income/Loss:
$-21.37M
P/E Ratio:
-0.8571
EPS:
-1.82
Net Cash Flow:
$-21.10M
1W Performance:
-4.29%
1M Performance:
-6.02%
6M Performance:
+20.00%
1Y Performance:
-36.07%
1-Day Range:
$1.50
$1.70
1-Week Range:
$1.50
$1.73
52-Week Range:
$0.89
$5.33
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.56 | 41.38M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - MSN
Institutional investors may overlook Regulus Therapeutics Inc.'s (NASDAQ:RGLS) recent US$12m market cap drop as long-term gains remain positive - Simply Wall St
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Gain Therapeutics' SWOT analysis: protein misfolding stock faces pivotal phase - Investing.com India
Quince Therapeutics, Inc. (NASDAQ:QNCX) Sees Large Increase in Short Interest - MarketBeat
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Stock market news: Wintest surges 26.25%, Smaregi drops 16.74%, D. Western Therapeutics gains 25.96% in volatile midday trading - Business Upturn
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Short Interest Update - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Sees Significant Increase in Short Interest - MarketBeat
NCATS Helped Develop a Gene Therapy for a Rare Brain Disorder - NCBI
Crude Oil Gains Over 1%; RH Shares Jump On Strong Forecast - Benzinga
Baxter Stock May Gain Following Five New Injectable Product Launches - Yahoo Finance
Gain Therapeutics To Present At Biotech Showcase 2025 - The Manila Times
Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15% - Yahoo Finance
Design Therapeutics Gains 11%, Insider Trades Reap Benefit - Simply Wall St
Biotech's Parkinson's Drug Could Be Worth US$4B, Analyst Says - Streetwise Reports
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain? - Yahoo Finance
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains - Yahoo Finance
Roth Mkm Begins Coverage on Gain Therapeutics (NASDAQ:GANX) - Defense World
Gain Therapeutics (NASDAQ:GANX) Upgraded at Roth Capital - Defense World
GANX shares initiated with buy rating on preclinical trials By Investing.com - Investing.com Canada
Roth MKM Initiates Coverage of Gain Therapeutics (GANX) with Buy Recommendation - MSN
GANX shares initiated with buy rating on preclinical trials - Investing.com
Gain Therapeutics' SWOT analysis: protein misfolding drug developer's stock outlook - Investing.com Canada
TMO Stock to Gain From the New Additions to CTS Portfolio of Products - Yahoo Finance
Dow Gains 250 Points; Salesforce Shares Jump After Q3 Results - Benzinga
Health Care Down, But Near All-Time Highs, as Biotech Firms Gain -- Health Care Roundup - Marketscreener.com
PTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz Grows - MSN
2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money
Gene Therapy Explosion Forces Employer Coverage to Get Creative - Bloomberg Law
S&P 500, Dow close at record highs on tech gains - Yahoo Finance
Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million - Yahoo Finance
The 3.8% return this week takes United Therapeutics' (NASDAQ:UTHR) shareholders five-year gains to 314% - Yahoo Finance
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Increase in Short Interest - MarketBeat
HC Wainwright Lifts Earnings Estimates for Gain Therapeutics - Defense World
HC Wainwright Reaffirms “Buy” Rating for Gain Therapeutics (NASDAQ:GANX) - Defense World
Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Stock market today: Poseida Therapeutics +224.30%, Primega Group Holdings +98.77% among the top gainers in early trading - Business Upturn
BSX Stock Set to Gain From Agreement to Acquire Intera Oncology - Yahoo Finance
Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs - Yahoo Finance
Gain Therapeutics shares hold Buy rating; H.C. Wainwright optimistic on GT-02287 clinical data - Investing.com India
FY2024 Earnings Forecast for GANX Issued By Chardan Capital - Defense World
Drug developer stocks slide further in fall, despite gains from Exelixis and Xencor - BioWorld Online
FATE Presents Encourgaing Data From Lupus Study, Stock Gains - Nasdaq
Stock Market News: Aclaris Therapeutics gains over 55% while Exicure increases almost 31% during mid day trading - Business Upturn
Stock market news: Renewable Japan jumps nearly 69% by mid-day, D. Western Therapeutics and Agile Media Network post strong gains - Business Upturn
Gain Therapeutics Advances Parkinson’s Therapy Development - TipRanks
Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 15.1% in October - Defense World
Chesapeake Granite Wash Trust (OTCMKTS:CHKR) Sees Large Increase in Short Interest - Defense World
PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright - Defense World
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gain Therapeutics Inc Stock (GANX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Islam Khalid | Executive Chairman |
Aug 09 '24 |
Buy |
1.00 |
50,000 |
49,940 |
50,000 |
| RICHMAN ERIC I | Director |
Jul 01 '24 |
Buy |
1.22 |
17,000 |
20,670 |
289,629 |
| Riley Jeffrey Scott | Director |
Mar 28 '24 |
Buy |
3.86 |
30,000 |
115,770 |
30,000 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):